ReviewWorld journal of gastroenterology2014
Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review.World journal of gastroenterology · 2016Pooled it
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.World journal of gastroenterology · 2017Trial
- Effect of exercise and pharmacotherapy on non-alcoholic fatty liver disease.SAGE open medicine · 2024Article
- Total Flavonoids fromFoods (Basel, Switzerland) · 2022Article
- Association between nonalcoholic fatty liver disease andSaudi medical journal · 2021Article
- Prebiotic Impacts of Soybean Residue (Okara) on Eubiosis/Dysbiosis Condition of the Gut and the Possible Effects on Liver and Kidney Functions.Molecules (Basel, Switzerland) · 2021Review
- Article
- Medications in type-2 diabetics and their association with liver fibrosis.World journal of gastroenterology · 2020Article
- The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease.International journal of environmental research and public health · 2020Article
- Mitigation of nonalcoholic fatty liver disease in high-fat-fed mice by the combination of decaffeinated green tea extract and voluntary exercise.The Journal of nutritional biochemistry · 2020Article
- Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice.World journal of hepatology · 2019Article
- Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD.Diseases (Basel, Switzerland) · 2018Review
- Bitter melon extract ameliorates palmitate-induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 cells and high-fat/high-fructose-diet-induced fatty liver.Food & nutrition research · 2018Article
- Three-dimensional perfused humanWorld journal of gastroenterology · 2017Article
- Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.World journal of gastroenterology · 2016Article
- An Oral Load of [13C3]Glycerol and Blood NMR Analysis Detect Fatty Acid Esterification, Pentose Phosphate Pathway, and Glycerol Metabolism through the Tricarboxylic Acid Cycle in Human Liver.The Journal of biological chemistry · 2016Article
- Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis.Case reports in endocrinology · 2016Article
- Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD.Cell & bioscience · 2016Review
- Management of non-alcoholic fatty liver disease in 2015.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disorder in Western countries and is increasingly being recognized in developing nations. Fatty liver disease encompasses a spectrum of hepatic pathology, ranging from simple steatosis to non-alcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma and end-stage liver disease. Moreover, NAFLD is often associated with other metabolic conditions, such as diabetes mellitus type 2, dyslipidemia and visceral obesity. The most recent guidelines suggest the management and treatment of patients with NAFLD considering both the liver disease and the associated metabolic co-morbidities. Diet and physical exercise are considered the first line of treatment for patients with NAFLD, but their results on therapeutic efficacy are often contrasting. Behavior therapy is necessary most of the time to achieve a sufficient result. Pharmacological therapy includes a wide variety of classes of molecules with different therapeutic targets and, often, little evidence supporting the real efficacy. Despite the abundance of clinical trials, NAFLD therapy remains a challenge for the scientific community, and there are no licensed therapies for NAFLD. Urgently, new pharmacological approaches are needed. Here, we will focus on the challenges facing actual therapeutic strategies and the most recent investigated molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.